Method for synthesizing Apremilast
A continuous process for synthesizing apremilast using acid-catalyzed condensation in DMSO solvent with direct crystallization addresses the inefficiencies of existing methods, reducing reaction time and waste while enhancing scalability.
Patent Information
- Application Number
- JP2023565491
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-04-26
- Filing Date
- 2022-04-25
- Publication Date
- 2026-11-19
- Estimated Expiration
- 2042-04-25
AI Technical Summary
Existing methods for synthesizing apremilast are lengthy, generate significant waste, and require resource-intensive downstream processing steps.
A continuous process involving the acid-catalyzed condensation of 3-acetamidophthalic anhydride and (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethan-1-amine in a polar aprotic solvent like DMSO, with controlled temperature and addition of water for direct crystallization, eliminating the need for aqueous post-treatment and distillation.
The process significantly reduces reaction time, minimizes waste, and simplifies the manufacturing footprint by enabling direct crystallization of apremilast, making it suitable for industrial scale-up.
Smart Images

Figure 0007954163000003 
Figure 0007954163000004 
Figure 0007954163000005
Abstract
Description
TECHNICAL FIELD
[0001] The disclosure provided herein relates to a method for synthesizing (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoisoindoline-1,3-dione (apremilast), and embodiments of this method relate to continuous processes for synthesizing apremilast and batch processes for synthesizing apremilast. BACKGROUND ART
[0002] Apremilast is a member of the class of isoindolines substituted at the 4-position with an acetamido group and at the 1-position with a 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl group. It functions as a phosphodiesterase IV inhibitor and a non-steroidal anti-inflammatory agent, and has the following chemical structure. CHEMICAL FORMULA
[0003] Apremilast can be formed by an acid-catalyzed condensation reaction between 3-acetamidophthalic anhydride (Compound A) and (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethan-1-amine (Compound B). CHEMICAL FORMULA
[0004] This reaction can proceed by various means. One such example is via acid-catalyzed condensation of Compound (A) and Compound (B) in an organic solvent (e.g., tetrahydrofuran, THF) containing a catalytic amount of water. The acid-catalyzed reaction requires heating the reaction mixture at 72°C for about 16 hours to obtain crude apremilast. Isolation of the crude product from the reaction mixture then requires a series of aqueous workup steps, followed by a distillation process, and finally crystallization from a mixture of solvents such as isopropyl acetate / methyl tert-butyl ether.
[0005] Processes that produce apremilast benefit from shorter cycle times, resulting in reduced reaction times, decreased waste generation due to the elimination of aqueous post-treatment steps, and a smaller, more flexible manufacturing footprint. [Overview of the Initiative] [Means for solving the problem]
[0006] This specification provides a method for preparing apremilast, comprising the steps of: (1) mixing a first solution containing 3-acetamidophthalic anhydride (compound A) or a salt thereof in a first solvent; and (2) mixing a second solution containing (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B) or a salt thereof in a second solvent to form apremilast in a reaction mixture; and adding water to the reaction mixture to isolate the apremilast. In various embodiments, the mixing is carried out in a plug-flow reactor.
[0007] In some embodiments, the mixing is carried out in the presence of an acid. In some embodiments, the acid is an alkyl sulfonic acid, an aryl sulfonic acid, an alkyl carboxylic acid, or an aryl carboxylic acid. In some embodiments, the acid is selected from the group consisting of acetic acid, methyl sulfonic acid, tolylsulfonic acid, trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, chloroacetic acid, benzenesulfonic acid, trifluic acid, ethylsulfonic acid, formic acid, propionic acid, benzoic acid, salicylic acid, and oxalic acid. In some embodiments, the acid includes acetic acid. The acid may be present in an amount of 0.01 to 20 (or 0.5 to 3 or 1 to 2.5) volume equivalents based on compound B or a salt thereof.
[0008] In some embodiments, the mixing is carried out in the presence of up to 1.5 (or 0.5) molar equivalents of water based on compound B or a salt thereof, while in other embodiments, the mixing is carried out in the absence of water.
[0009] In various embodiments, compound A or a salt thereof exists in 0.4 to 1.5 (or 0.8 to 1.2, or 0.99) molar equivalents based on compound B or a salt thereof. In various embodiments, compound A exists as a neutral species (i.e., not in salt form). In various embodiments, compound B exists as a neutral species (i.e., not in salt form), but in other embodiments, compound B exists in salt form.
[0010] In various embodiments, the first and second solvents are the same solvent, but in other embodiments, the first and second solvents are different solvents. In various embodiments, the first and / or second solvent is a polar aprotic solvent. In various embodiments, the polar aprotic solvent has a boiling point of about 40°C to about 200°C at 1 atm. In various embodiments, the polar aprotic solvent contains 0 to 10% by weight of water, but in other embodiments, the polar aprotic solvent is anhydrous. In various embodiments, the polar aprotic solvent has a dielectric constant of 10 to 50 at room temperature and 1 atm. In various embodiments, the polar aprotic solvent is acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAC), N-methyl-2-pyrrolidone (NMP), hexamethylphosphoramide (HMPA), N,N'-dimethylpropylene urea (DMPU), sulfolane, dihydrolevoglucocenone, 1,3-dimethyl-2-imidazolidinone (DMI), or a combination thereof. In various embodiments, the polar aprotic solvent includes DMSO.
[0011] In various embodiments, mixing is carried out at temperatures of 20°C to 200°C, 50°C to 200°C, 70°C to 190°C, 130°C to 135°C, or 70°C to the reflux temperature of the solvent. In some embodiments, mixing is carried out at temperatures of 20°C to 200°C, 50°C to 200°C, 70°C to 190°C, 130°C to 135°C, or 70°C to the reflux temperature of the solvent. The reaction time is 0.1 minutes to 48 hours, or 4 hours to 36 hours, or 8 hours to 24 hours, or 16 hours. In some embodiments, mixing is performed with a residence time of 0.1 minutes to 120 minutes, or 1 minute to 60 minutes, or 10 minutes to 40 minutes, or 15 minutes to 30 minutes, or 25 minutes to 30 minutes. In some embodiments, mixing is performed with a residence time of 35 minutes.
[0012] In various embodiments, isolation includes (a) cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooling solution, (b) adding water to the cooling solution, and (c) precipitating the apremilast from the solution formed in step (b) to isolate the apremilast. In various embodiments, the method further includes filtering the precipitated apremilast from step (c). In various embodiments, step (b) further includes adding crystalline apremilast to the cooling solution such that the precipitate from step (c) yields crystalline apremilast.
[0013] In various embodiments, isolation includes continuous crystallization using a mixed suspension mixed product removal (MSMPR) crystallizer, parallel filtration, or a combination thereof.
[0014] Furthermore, a method is provided for isolating apremilast from a reaction mixture containing crude apremilast and DMSO, comprising: (a) cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooling solution; (b) adding water to the cooling solution; (c) precipitating apremilast from the solution formed in step (b) to form precipitated apremilast; and (d) isolating the precipitated apremilast. In various embodiments, isolation is performed by filtration. In various embodiments, step (b) further includes adding crystalline apremilast to the cooling solution. In various embodiments, the precipitated apremilast is crystalline.
[0015] Furthermore, a method for preparing apremilast is provided, comprising: (a) a step of mixing (1) a first solution containing 3-acetamidophthalic anhydride (compound A) in a first solvent and (2) a second solution containing (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B) or a salt thereof in a second solvent to form apremilast in a reaction mixture, wherein the mixing is performed in a continuous process apparatus; and (b) a step of isolating the apremilast from the reaction mixture, wherein the isolation step comprises: (i) a step of cooling the reaction mixture to a temperature of 0°C to 50°C; (ii) a step of adding water to the cooled reaction mixture; (iii) a step of precipitating the apremilast from the mixture in step (ii); and (iv) a step of isolating the precipitated apremilast.
[0016] Furthermore, a method for preparing crystalline apremilast is provided, comprising: (a) mixing (1) a first solution containing 3-acetamidophthalic anhydride (compound A) in a first solvent and (2) a second solution containing (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B) or a salt thereof in a second solvent to form apremilast in a reaction mixture, wherein the mixing is performed in a continuous process apparatus; and (b) isolating the crystalline apremilast from the reaction mixture by continuous crystallization and parallel filtration. In various embodiments, continuous crystallization includes the use of a mixed suspension mixed product removal (MSMPR) crystallizer. [Brief explanation of the drawing]
[0017] [Figure 1] Figure 1 shows a process flow diagram of the continuous reaction process and the continuous crystallization of apremilast disclosed herein. [Figure 2] Figure 2 shows a process flow diagram of the continuous reaction process and apremilast manufacturing process disclosed herein. [Figure 3A] Figure 3A shows the XRPD plot of crystalline morphology B of apremilast disclosed herein. [Figure 3B] Figure 3B shows a representative DVS plot of crystalline Form B of apremilast. [Mode for Carrying Out the Invention]
[0018] The following description relates to various exemplary embodiments of the processes of the present disclosure. However, the disclosed embodiments should not be construed or used to limit the scope of the present disclosure, including the claims. Furthermore, those skilled in the art will appreciate that the following description has a wide range of applications, and the description of any embodiment is merely illustrative of that embodiment, and the scope of the present disclosure, including the claims, is not limited to that embodiment.
[0019] As used herein, the terms "including" and "comprising" are used in an open-ended fashion, and thus should be interpreted to mean "including, but not limited to...". As used herein, the term "about", when used in combination with a percentage or other numerical value, means plus or minus 10% of that percentage or other numerical value. For example, the term "about 80%" encompasses 80% plus or minus 8%.
[0020] Process for synthesizing apremilast Provided herein are processes for obtaining apremilast. Further provided herein are methods for isolating and crystallizing apremilast.
[0021] In some embodiments, the present disclosure provides a method for preparing apremilast, comprising the steps of: (1) mixing a first solution comprising 3-acetamidophthalic anhydride (Compound A) or a salt thereof in a first solvent, and (2) a second solution comprising (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethan-1-amine (Compound B) or a salt thereof in a second solvent, to form apremilast in the reaction mixture; and adding water to the reaction mixture to isolate apremilast. In some embodiments, the process for synthesizing apremilast is a continuous reaction process. In some embodiments, the process for synthesizing apremilast is a batch process.
[0022] In some embodiments, a continuous process (or continuous manufacturing (CM)) comprises a) continuously feeding input materials into the process, b) continuously converting in-process materials within the process, and / or c) continuously withdrawing output materials from the process. In some embodiments of the continuous process, two or more unit operations are directly connected, wherein a unit operation can be defined as a fundamental step of the process that includes, but is not limited to, physical changes or chemical transformations such as reaction, crystallization, distillation, and purification. In some embodiments, the continuous process can be applied to some or all unit operations.
[0023] A continuous process can comprise a combination of manufacturing approaches, where some unit operations operate in batch mode while other unit operations are integrated to operate in continuous mode. In some cases, the process is integrated and operates in continuous mode. In some embodiments, the continuous reaction process can incorporate surge lines or tanks to maintain a constant flow of material input and output in any mode of the continuous reaction processes described herein.
[0024] In some embodiments, the continuous reaction process is a sequence of chemical transformations, solvent changes, and purification steps, and may include the integration of typical unit operations used in pharmaceutical raw material processes into a continuous process. In some embodiments, the integrated process may include a plug-flow reactor (PFR), where, for example, PFR design elements (e.g., dimensions and configuration) allow for precise control of temperature, mixing and reactant flow, continuous stirred tank reactor (CSTR), homogeneous and heterogeneous phase extraction, continuous crystallization, and / or filtration. In some embodiments, starting materials can be combined in the PFR to produce a crude product, which can then be purified by extraction and continuous crystallization. The crystallized slurry can be filtered using units that run alternately, allowing for continuous processing of pharmaceutical raw materials after crystallization.
[0025] Starting materials / reactants In the method of this disclosure, a solution of compound A or a salt thereof and a solution of compound B or a salt thereof are mixed together to form an apremilast. In some cases, compound A may exist as a neutral species (i.e., not as a salt). In some cases, compound A may exist in salt form. In some embodiments, the salt form of compound A may be an alkali metal salt or an alkaline earth metal salt. Some specifically intended salt forms include, but are not limited to, calcium salts, magnesium salts, sodium salts, lithium salts, zinc salts, potassium salts, and iron salts. In some cases, compound B may exist as a free base (i.e., not as a salt) or as a neutral amine compound. In some cases, compound B may exist in salt form. In some embodiments, the salt form of compound B may be acetate, benzenesulfonate, benzoate, bicarbonate, tartrate, bromide, calcium edetate, cansylate, carbonate, chloride, bromide, iodide, citrate, dihydrochloride, edetate, edisylate, estrate, esitate, fumarate, gluceptate, gluconate, glutamate, glycolyl arsanylate, hexylresorcinate, hydravamin, hydroxynaphthoate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylsulfate, mustine, leucine, napsylate, nitrate, pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, succinic acid, sulfate, tannate, tartrate, theocrate, triethiozide, or pamoate.
[0026] Compound A or its salt may exist in amounts of 10 molar equivalents or less based on compound B or its salt, for example, 9.5 molar equivalents, 9 molar equivalents, 8.5 molar equivalents, 8 molar equivalents, 7.5 molar equivalents, 7 molar equivalents, 6.5 molar equivalents, 6 molar equivalents, 5.5 molar equivalents, 5 molar equivalents, 4.5 molar equivalents, 4 molar equivalents, 3.5 molar equivalents, 3 molar equivalents, 2.5 molar equivalents, 2 molar equivalents, 1.5 molar equivalents, 1 molar equivalent, 0.5 molar equivalents, 0.4 molar equivalents, 0.3 molar equivalents, 0.2 molar equivalents, or 0.1 molar equivalents, or less. Alternatively, or in addition thereto, in various embodiments, the present disclosure provides a method for preparing an apremilast, wherein compound A or a salt thereof is present in an amount of 0.1 molar equivalent or more, for example, 0.1 molar equivalent, 0.2 molar equivalent, 0.3 molar equivalent, 0.4 molar equivalent, 0.5 molar equivalent, 1 molar equivalent, 1.5 molar equivalent, 2 molar equivalent, 2.5 molar equivalent, 3 molar equivalent, 3.5 molar equivalent, 4 molar equivalent, 4.5 molar equivalent, 5 molar equivalent, 6 molar equivalent, 6.5 molar equivalent, 7 molar equivalent, 7.5 molar equivalent, 8 molar equivalent, 8.5 molar equivalent, 9 molar equivalent, 9.5 molar equivalent, or 10 molar equivalent, or more, based on compound B or a salt thereof. Accordingly, in some embodiments, the Disclosure provides a method for preparing an apremilast, wherein compound A or a salt thereof may be present in an amount constrained by and containing any combination of the endpoints described above. In various embodiments, the Disclosure provides a method for preparing an apremilast, wherein compound A or a salt thereof is present in an amount of 0.4 to 1.5 molar equivalents based on compound B or a salt thereof. In some other embodiments, compound A or a salt thereof is present in an amount of 0.8 to 1.2 molar equivalents based on compound B or a salt thereof. In some embodiments, compound A or a salt thereof is present in an amount of 0.99 molar equivalents based on compound B or a salt thereof.
[0027] solvent A solution of compound A or its salt is in a first solvent. A solution of compound B or its salt is in a second solvent. In some embodiments, the first and second solvents are the same solvent. In some other embodiments, the first and second solvents are different solvents.
[0028] The first and / or second solvent is any solvent suitable for the condensation reaction that forms apremilast. For example, the solvent may be selected to obtain stability at the operating temperature of the process of this disclosure. Thus, the solvent may be selected so that thermal decomposition is minimal or nonexistent under the conditions of the process. The selected solvent may be chosen so as not to cause adverse interactions with the reactants, intermediates, or process products and not to reduce the yield of apremilast. The solvent may be selected to increase the solubility of the reactants (compounds A and / or B) and to allow for improved homogeneity of the reaction mixture. The solvent may facilitate acceleration of the reaction rate by facilitating safe operation at high temperatures. The solvent may also allow for the direct crystallization of apremilast from the reactant mixture (e.g., by the addition of water).
[0029] In various embodiments, the solvent is a polar aprotic solvent. As used herein, “polar aprotic solvent” refers to a solvent lacking OH or NH bonds that has a dielectric constant (ε) greater than 6 and a dipole moment greater than 1.5D when measured at 20–25°C (room temperature). In some embodiments, the polar aprotic solvent has a dielectric constant of 10–60 at room temperature and 1 atm. In some embodiments, the polar aprotic solvent has a dielectric constant of 20–55 at room temperature and 1 atm. In some embodiments, the polar aprotic solvent has a dielectric constant of 30–50 at room temperature and 1 atm.
[0030] The solvent can have any suitable boiling point, as long as it is stable under process conditions (e.g., reaction temperature and pressure) so that the solvent does not undergo significant thermal decomposition. In some embodiments, polar aprotic solvents have boiling points of about 40°C to about 200°C at 1 atm. The solvent may have boiling points above 40°C, for example, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, 150°C, 155°C, 160°C, 165°C, 170°C, 175°C, 180°C, 185°C, 190°C, 195°C, or 200°C or higher. Alternatively, or in addition, in various embodiments, the solvent may have a boiling point of 200°C or less, for example, 195°C, 190°C, 185°C, 180°C, 175°C, 170°C, 165°C, 160°C, 155°C, 150°C, 145°C, 135°C, 130°C, 125°C, 120°C, 115°C, 110°C, 110°C, 105°C, 100°C, 95°C, 90°C, 85°C, 80°C, 75°C, 75°C, 70°C, 65°C, 60°C, 55°C, 50°C, or 45°C, or lower. Therefore, in some embodiments, the boiling point of the selected solvent may be constrained by any combination of the aforementioned endpoints and may include temperatures that encompass them.
[0031] In some embodiments, the polar aprotic solvent has 10% by weight or less of water, for example, 9% by weight, 8% by weight, 7% by weight, 6% by weight, 5% by weight, 4% by weight, 3% by weight, 2% by weight, or 1% by weight or less. In some specific embodiments, the polar aprotic solvent is anhydrous.
[0032] Specific polar aprotic solvents intended for use in the processes of this disclosure include acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAC), N-methyl-2-pyrrolidone (NMP), hexamethylphosphoramide (HMPA), N,N'-dimethylpropylene urea (DMPU), sulfolane, dihydrolevoglucocenone, 1,3-dimethyl-2-imidazolidinone (DMI), or combinations thereof. In some embodiments, the polar aprotic solvent includes dimethyl sulfoxide (DMSO). The use of polar aprotic solvents such as DMSO as the reaction solvent has been shown to result in the following improvements: 1) accelerated reaction rates due to safe operation at high temperatures, 2) increased solubility of reactants enabling a homogeneous reaction solution, and 3) direct crystallization of apremilast from the crude reaction stream, eliminating the need for time-consuming and resource-intensive downstream processing steps.
[0033] Other additives for the process disclosed herein In some embodiments, the methods of the present disclosure can be carried out in the presence of an acid. In some embodiments, the acid is an alkyl sulfonic acid, an aryl sulfonic acid, an alkyl carboxylic acid, or an aryl carboxylic acid. In some embodiments, the acid is selected from the group consisting of acetic acid, methyl sulfonic acid, tolylsulfonic acid, trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, chloroacetic acid, benzenesulfonic acid, trifluic acid, ethylsulfonic acid, formic acid, propionic acid, benzoic acid, salicylic acid, and oxalic acid. In some embodiments, the acid includes acetic acid.
[0034] The acid is 20 volume equivalents or less based on compound B or its salt, for example, 20 volume equivalents, 19.5 volume equivalents, 19 volume equivalents, 18.5 volume equivalents, 18 volume equivalents, 17.5 volume equivalents, 17 volume equivalents, 16.5 volume equivalents, 16 volume equivalents, 15.5 volume equivalents, 14 volume equivalents, 13.5 volume equivalents, 13 volume equivalents, 12.5 volume equivalents, 12 volume equivalents, 11.5 volume equivalents, 11 volume equivalents, 10.5 volume equivalents, 10 volumes equivalents It may exist in the form of a volume equivalent, 9.5 volume equivalents, 9 volume equivalents, 8.5 volume equivalents, 8 volume equivalents, 7.5 volume equivalents, 7 volume equivalents, 6.5 volume equivalents, 6 volume equivalents, 5.5 volume equivalents, 5 volume equivalents, 4.5 volume equivalents, 4 volume equivalents, 3.5 volume equivalents, 3 volume equivalents, 2.5 volume equivalents, 2 volume equivalents, 1.5 volume equivalents, 1 volume equivalent, 0.5 volume equivalents, 0.4 volume equivalents, 0.3 volume equivalents, 0.2 volume equivalents, or 0.1 volume equivalents. Alternatively, or in addition thereto, in various embodiments, the acid may be 0.01 volume equivalent or more based on compound B or a salt thereof, for example, 0.1 volume equivalent, 0.2 volume equivalent, 0.3 volume equivalent, 0.4 volume equivalent, 0.5 volume equivalent, 1 volume equivalent, 1.5 volume equivalent, 2 volume equivalent, 2.5 volume equivalent, 3 volume equivalent, 3.5 volume equivalent, 4 volume equivalent, 4.5 volume equivalent, 5 volume equivalent, 6 volume equivalent, 6.5 volume equivalent, 7 volume equivalent, 7.5 volume equivalent The acid exists in volumes of 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20. Therefore, in some embodiments, the acid may exist in volumes based on compound B or a salt thereof, including any combination of the endpoints described above. For example, the acid may exist in volumes from 0.01 to 20 based on compound B or a salt thereof. In some cases, the acid is present in 0.1 to 10 volume equivalents based on compound B or its salt. In some cases, the acid is present in 0.5 to 3 volume equivalents based on compound B or its salt. In some cases, the acid is present in 1 to 2.5 volume equivalents based on compound B or its salt.
[0035] The acid is based on compound B or its salt and is 20 molar equivalents or less, for example, 20 molar equivalents, 19.5 molar equivalents, 19 molar equivalents, 18.5 molar equivalents, 18 molar equivalents, 17.5 molar equivalents, 17 molar equivalents, 16.5 molar equivalents, 16 molar equivalents, 15.5 molar equivalents, 14 molar equivalents, 13.5 molar equivalents, 13 molar equivalents, 12.5 molar equivalents, 12 molar equivalents, 11.5 molar equivalents, 11 molar equivalents, 10.5 molar equivalents, 10 molar equivalents. It may exist in the form of 1 molar equivalent, 9.5 molar equivalent, 9 molar equivalent, 8.5 molar equivalent, 8 molar equivalent, 7.5 molar equivalent, 7 molar equivalent, 6.5 molar equivalent, 6 molar equivalent, 5.5 molar equivalent, 5 molar equivalent, 4.5 molar equivalent, 4 molar equivalent, 3.5 molar equivalent, 3 molar equivalent, 2.5 molar equivalent, 2 molar equivalent, 1.5 molar equivalent, 1 molar equivalent, 0.5 molar equivalent, 0.4 molar equivalent, 0.3 molar equivalent, 0.2 molar equivalent, or 0.1 molar equivalent. Alternatively, or in addition thereto, in various embodiments, the acid may be 0.01 molar equivalents or more based on compound B or its salt, for example, 0.1 molar equivalents, 0.2 molar equivalents, 0.3 molar equivalents, 0.4 molar equivalents, 0.5 molar equivalents, 1 molar equivalent, 1.5 molar equivalents, 2 molar equivalents, 2.5 molar equivalents, 3 molar equivalents, 3.5 molar equivalents, 4 molar equivalents, 4.5 molar equivalents, 5 molar equivalents, 6 molar equivalents, 6.5 molar equivalents, 7 molar equivalents, 7.5 molar equivalents, based on compound B or its salt. The acid exists in amounts of 8 molar equivalents, 8.5 molar equivalents, 9 molar equivalents, 9.5 molar equivalents, 10 molar equivalents, 10.5 molar equivalents, 11 molar equivalents, 11.5 molar equivalents, 12 molar equivalents, 12.5 molar equivalents, 13 molar equivalents, 13.5 molar equivalents, 14 molar equivalents, 14.5 molar equivalents, 15 molar equivalents, 15.5 molar equivalents, 16 molar equivalents, 16.5 molar equivalents, 17 molar equivalents, 17.5 molar equivalents, 18 molar equivalents, 18.5 molar equivalents, 19 molar equivalents, 19.5 molar equivalents, or 20 molar equivalents. Therefore, in some embodiments, the acid may exist in molar equivalents based on compound B or a salt thereof, including any combination of the endpoints described above. For example, the acid may exist in amounts from 0.01 to 20 molar equivalents based on compound B or a salt thereof. In some cases, the acid is present in amounts of 0.1 to 15 molar equivalents based on compound B or its salt. In some cases, the acid is present in amounts of 5 to 12 molar equivalents based on compound B or its salt. In some cases, the acid is present in amounts of 11 to 12 molar equivalents based on compound B or its salt.
[0036] In some embodiments, mixing is carried out in the presence of up to 1.5 molar equivalents of water based on compound B or its salt; in some embodiments, up to 1.25 molar equivalents of water based on compound B or its salt; in some embodiments, up to 1 molar equivalent of water based on compound B or its salt; in some embodiments, up to 0.75 molar equivalents of water based on compound B or its salt; in some embodiments, water is present in 0.5 molar equivalents based on compound B or its salt; in various embodiments, water is present in 0.25 molar equivalents based on compound B or its salt; in some embodiments, water is absent.
[0037] temperature As disclosed herein, the process for preparing apremilast can be carried out at a range of temperatures. The methods of this disclosure can be carried out at higher temperatures compared to previous apremilast synthesis, thereby shortening the reaction time, allowing the reaction to be carried out over hours or minutes compared to days. Thus, synthesizing apremilast as described herein is practical, toward appropriate yields, particularly suitable for industrial scale-up, and results in cost reductions and reductions in solvent waste associated with these processes. Accordingly, in some embodiments, this disclosure provides a method for preparing apremilast, wherein the mixing of compound A and compound B can be carried out at a temperature of 20°C to 200°C. In some embodiments, the mixing is carried out at 70°C to the reflux temperature of the solvent. In some embodiments, the mixing is carried out at a temperature of 50°C to 200°C. In some embodiments, the mixing is carried out at a temperature of 70°C to 190°C. In various embodiments, the mixing is carried out at a temperature of 130°C to 135°C. In various embodiments, the mixing is carried out at temperatures of 20°C or higher, for example, 25°C, 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, 150°C, 155°C, 160°C, 165°C, 170°C, 175°C, 180°C, 185°C, 190°C, 195°C, 200°C, 205°C, or 210°C or higher. Alternatively, or in addition thereto, in various embodiments, the Disclosure provides a method for preparing apremilast, wherein the mixing is carried out at a temperature of 210°C or lower, for example, 205°C, 200°C, 195°C, 190°C, 185°C, 180°C, 175°C, 170°C, 165°C, 160°C, 155°C, 150°C, 145°C, 135°C, 130°C, 125°C, 120°C, 115°C, 110°C, 110°C, 105°C, 100°C, 95°C, 90°C, 85°C, 80°C, 75°C, 75°C, 70°C, 65°C, 60°C, 55°C, 50°C, 45°C, 40°C, 35°C, 30°C or lower.Accordingly, in some embodiments, the present disclosure provides a method for preparing an apremilast, wherein the mixing is constrained by any combination of the above-described endpoints and is carried out at a temperature including such endpoints.
[0038] Reaction time As disclosed herein, the process for preparing apremilast may be carried out over a range of reaction times, which may provide a commercially viable reaction time. In some embodiments, the mixing of compound A and compound B is carried out over an average reaction time of 0.1 minutes to 48 hours, as described above. In some embodiments, the mixing is carried out over an average reaction time of 4 hours to 36 hours. In some embodiments, the mixing is carried out over an average reaction time of 8 to 24 hours. In some embodiments, the mixing is carried out over an average reaction time of 16 hours. In various embodiments, the mixing is carried out over a range of 5 minutes to 16 hours, for example, 15 minutes, 30 minutes, or 45 minutes, or longer. In some cases, mixing may take place over a period of 16 hours or less, for example, 15.5 hours or less, 15 hours or less, 14.5 hours or less, 14 hours or less, 13.5 hours or less, 13 hours or less, 12.5 hours or less, 12 hours or less, 11.5 hours or less, 11 hours or less, 10.5 hours or less, 10 hours or less, 9.5 hours or less, 9 hours or less, 8.5 hours or less, 8 hours or less, 7.5 hours or less, 7 hours or less, 6.5 hours or less, 6 hours or less, 5.5 hours or less, 5 hours or less, 4.5 hours or less, 4 hours or less, 3.5 hours or less, 3 hours or less, 2.5 hours or less, 2 hours or less, 1.5 hours or less, or 1 hour or less. In various embodiments, mixing may take place over a period of 1 to 4 hours.
[0039] Duration of stay In certain embodiments, mixing is carried out as a continuous reaction process. For example, the reaction can be carried out in a plug-flow reactor (PFR). A plug-flow reactor can be used in a continuous reaction process where the concentration and temperature of the reactants (e.g., compound A or a salt thereof in a first solvent and compound B or a salt thereof in a second solvent) are uniform. A plug-flow reactor has a fixed residence time (τ). The reaction mixture passing through the PFR can be processed as it flows through a reactor which is a series of cohesive "plugs," each having a uniform configuration that moves only in the axial direction of the reactor. As the plugs flow through the PFR, the reaction mixture is mixed radially. The average residence time (τ) in the PFR is the average time that the reactants spend in the PFR. Residence time refers to what is otherwise considered the "reaction time" in a conventional or batch process.
[0040] The process for preparing an apremilast as disclosed herein may be carried out over a range of residence times. The residence time may be 120 minutes or less, for example, 115 minutes, 110 minutes, 105 minutes, 100 minutes, 95 minutes, 90 minutes, 85 minutes, 80 minutes, 75 minutes, 70 minutes, 65 minutes, 60 minutes, 55 minutes, 50 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, 25 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 1 minute, 0.9 minutes, 0.8 minutes, 0.7 minutes, 0.6 minutes, 0.5 minutes, 0.4 minutes, 0.3 minutes, 0.2 minutes, or 0.1 minutes or less. Alternatively, or in addition, in various embodiments, the residence time may be 0.1 minutes or more, for example, 0.1 minutes, 0.2 minutes, 0.3 minutes, 0.4 minutes, 0.5 minutes, 0.6 minutes, 0.7 minutes, 0.8 minutes, 0.9 minutes, 1 minute, 1.5 minutes, 2 minutes, 2.5 minutes, 3 minutes, 3.5 minutes, 4 minutes, 4.5 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 65 minutes, 70 minutes, 75 minutes, 80 minutes, 85 minutes, 90 minutes, 95 minutes, 100 minutes, 110 minutes, 115 minutes, or 120 minutes or more. Thus, in some embodiments, mixing is performed within a residence time constrained by and including any combination of the endpoints described above. In various embodiments, mixing is carried out with residence times of 0.1 to 120 minutes, or 1 to 60 minutes, or 10 to 40 minutes, or 15 to 30 minutes, or 25 to 30 minutes, or 25 to 35 minutes.
[0041] Isolation of Apremilast Comparative methods for preparing apremilast from compound A and compound B were performed in tetrahydrofuran (see Example 9 in the Examples section below for a typical procedure using tetrahydrofuran). This process requires a long reaction time (at least 16 hours at 70-75°C). Isolation of crude apremilast from the THF reaction mixture requires a series of aqueous post-treatment steps, followed by a distillation step, and finally crystallization from a mixture of solvents such as isopropyl acetate and methyl tert-butyl ether. In consideration of the above, the present disclosure provides a process for easily isolating apremilast directly from the reaction mixture and producing crystalline apremilast.
[0042] Accordingly, in some embodiments, the present disclosure provides a method for preparing apremilast, further comprising the step of adding water to a reaction mixture to isolate the apremilast. In some embodiments, the step of isolating the apremilast from a reaction mixture includes (a) cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooled solution, (b) adding water to the cooled solution, and (c) precipitating the apremilast from the solution formed in step (b) to isolate the apremilast. In some embodiments, the method further includes filtering the precipitated apremilast from step (c). In some embodiments, step (b) further includes adding crystalline apremilast to the cooled solution such that the precipitate from step (c) yields crystalline apremilast. In some embodiments, the isolation step includes continuous crystallization using a mixed suspension mixed product removal (MSMPR) crystallizer, parallel filtration, or a combination thereof.
[0043] Cooling of the reaction mixture The cooling in step (b) is carried out at a temperature above 0°C, for example, 5°C, 10°C, 15°C, 20°C, 25°C, 30°C, 35°C, 40°C, or 45°C or higher. Alternatively, or in addition thereto, in various embodiments, the cooling is at a temperature below 50°C, for example, 45°C, 40°C, 35°C, 30°C, 25°C, 20°C, 15°C, 10°C or lower. Thus, in some embodiments, the cooling of the reaction mixture is at a temperature constrained by and including any combination of the endpoints described above. In some cases, the cooling includes cooling the mixture to room temperature (20-25°C).
[0044] Surprisingly, the use of DMSO as the reaction solvent has been found and disclosed herein to result in several process improvements, including promoting the direct crystallization of crude apremilast from the reaction mixture (or reaction flow), thereby eliminating the need for time-consuming and resource-intensive downstream processing steps. Seeding crystalline apremilast into the reaction mixture further enables the precipitation of crystalline apremilast. Accordingly, in some embodiments, the present disclosure provides a method for isolating apremilast from a reaction mixture comprising crude apremilast and DMSO, the method comprising: (a) cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooled solution; (b) adding water to the cooled solution; (c) precipitating apremilast from the solution formed in step (b) to form precipitated apremilast; and (d) isolating the precipitated apremilast. In some embodiments, step (b) further comprises adding crystalline apremilast to the cooled solution, resulting in precipitated apremilast being crystalline.
[0045] The crystalline apremilast formed by the method of this disclosure may be in any crystalline form. Various crystalline apremilast forms are described in detail in International Publication No. 2009 / 120167, the entire disclosure of which is incorporated by reference. In various embodiments, the crystalline apremilast formed by the method disclosed herein may be form A, form B, or form F. In some cases, the crystalline apremilast is form B. Form B can be characterized by X-ray powder diffraction analysis. A typical XRPD pattern of form B is shown in Figure 3. In certain embodiments, form B is characterized by XRPD peaks located at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 of the following approximate positions: 10.1, 12.4, 13.5, 15.7, 16.3, 18.1, 20.7, 22.5, 24.7, 26.2, 26.9, 29.1 degrees 2θ. In certain embodiments, morphology B is characterized by an XRPD pattern that matches the pattern shown in Figure 3. In certain embodiments, morphology B can be characterized by thermal analysis. A typical DSC plot of morphology B is shown in Figure 3. In certain embodiments, morphology B is characterized by a DSC plot that includes an endothermic event with an onset temperature of approximately 154°C. A typical TGA plot of morphology B is shown in Figure 3. In certain embodiments, morphology B is characterized by a TGA plot that includes a mass loss of less than approximately 1% of the total mass of the sample, e.g., approximately 0.25%, when heated from approximately 25°C to approximately 140°C. In certain embodiments, morphology B does not contain any substantial amount of water or any other solvent in the crystal lattice. In certain embodiments, morphology B is anhydrous. In certain embodiments, morphology B is not solvated. In certain embodiments, morphology B can be characterized by water sorption analysis. A typical water sorption isotherm plot is shown in Figure 3b. In certain embodiments, as RH increases from approximately 0% to approximately 95% RH, morphology B exhibits a mass change of less than approximately 1% of the starting mass of the sample, e.g., approximately 0.6%. In certain embodiments, the mass increased by adsorption is lost when RH decreases to approximately 0% RH. In certain embodiments, morphology B is substantially non-hygroscopic. In certain embodiments, the XRPD pattern of morphology B material remains substantially unchanged after adsorption / desorption analysis.In certain embodiments, form B is stable to humidity.
[0046] The continuous reaction process disclosed herein is an effective method for producing apremilast, partly because the reactants (compound A and compound B) are readily soluble in polar aprotic solvents such as DMSO, thereby resulting in a reaction flow suitable for use in a PFR. The reaction flow enters the PFR, and the reaction is facilitated by appropriate residence time and temperature within the PFR. The reaction flow, containing crude apremilast, can then undergo continuous crystallization, including the use of a mixed suspension mixed product removal (MSMPR) crystallizer. These continuous reaction processes then enable the isolation of crystalline apremilast without requiring intermediate isolation of crude apremilast or multiple solvent washes, thereby reducing reaction costs and production time.
[0047] In some embodiments, a reaction stream containing crude apremilast and water is mixed with crystalline apremilast in an MSMPR for seed crystallization to obtain crystalline apremilast. Thus, in some embodiments, the present disclosure provides a method for preparing apremilast, comprising the step of reacting compound A or a salt thereof with compound B or a salt thereof as described above, wherein the reaction occurs in a continuous reaction process apparatus and crude apremilast is formed in the reaction mixture. The method further comprises the step of isolating the apremilast from the reaction mixture. In various cases, the isolation step includes the steps of cooling the reaction mixture to a temperature of 0°C to 50°C, adding water to the cooled reaction mixture, precipitating the apremilast from the cooled reaction mixture, and isolating the precipitated apremilast.
[0048] In some embodiments, the Disclosure provides a method for preparing crystalline apremilast, comprising: a) mixing (1) a first solution containing compound A or a salt thereof in a first solvent and (2) a second solution containing compound B or a salt thereof in a second solvent to form apremilast in a reaction mixture, wherein the mixing is carried out in a continuous reaction process apparatus; and (b) isolating the crystalline apremilast from the reaction mixture by continuous crystallization and parallel filtration. In various cases, the isolation of crystalline apremilast may involve the use of a mixed suspension removal (MSMPR) crystallizer.
[0049] Embodiment 1. A method for preparing apremilast, (1) A first solution containing 3-acetamidophthalic anhydride (compound A) or a salt thereof in a first solvent, and (2) a second solution containing (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B) or a salt thereof in a second solvent, to form an apremilast in the reaction mixture, A method comprising the step of adding water to the reaction mixture to isolate apremilast. 2. The method according to Embodiment 1, wherein compound A or a salt thereof is present in an amount of 0.4 to 1.5 molar equivalents based on compound B or a salt thereof. 3. The method according to Embodiment 2, wherein compound A or a salt thereof is present in an amount of 0.8 to 1.2 molar equivalents based on compound B or a salt thereof. 4. The method according to Embodiment 3, wherein compound A or a salt thereof is present in an amount of 0.99 molar equivalents based on compound B or a salt thereof. 5. The method according to any one of Embodiments 1 to 4, wherein compound A is not in salt form. 6. The method according to any one of Embodiments 1 to 5, wherein the first solvent and the second solvent are the same solvent. 7. The method according to any one of Embodiments 1 to 6, wherein the first solvent and the second solvent are different solvents. 8. The method according to any one of Embodiments 1 to 7, wherein the first solvent is a polar aprotic solvent. 9. The method according to any one of Embodiments 1 to 8, wherein the second solvent is a polar aprotic solvent. 10. The method according to Embodiment 8 or 9, wherein the polar aprotic solvent has a boiling point of about 40°C to about 200°C at 1 atm. 11. The method according to any one of Embodiments 8 to 10, wherein the polar aprotic solvent has 0 to 10% by weight of water. 12. The method according to any one of Embodiments 8 to 10, wherein the polar aprotic solvent is anhydrous. 13. The method according to any one of Embodiments 8 to 12, wherein the polar aprotic solvent has a dielectric constant of 10 to 50 at room temperature and 1 atmosphere. 14. The method according to any one of Embodiments 8 to 13, wherein the polar aprotic solvent is acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAC), N-methyl-2-pyrrolidone (NMP), hexamethylphosphoramide (HMPA), N,N'-dimethylpropylene urea (DMPU), sulfolane, dihydrolevoglucocenone, 1,3-dimethyl-2-imidazolidinone (DMI), or a combination thereof. 15. The method according to any one of Embodiments 8 to 14, wherein the polar aprotic solvent comprises dimethyl sulfoxide (DMSO). 16. The method according to any one of embodiments 8 to 15, wherein the above mixing is carried out in the presence of an acid. 17. The method according to Embodiment 16, wherein the acid is an alkyl sulfonic acid, an aryl sulfonic acid, an alkyl carboxylic acid, or an aryl carboxylic acid. 18. The method according to Embodiment 16 or 17, wherein the acid is selected from the group consisting of acetic acid, methylsulfonic acid, tolylsulfonic acid, trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, chloroacetic acid, benzenesulfonic acid, trifluic acid, ethylsulfonic acid, formic acid, propionic acid, benzoic acid, salicylic acid, and oxalic acid. 19. The method according to any one of Embodiments 16 to 18, wherein the acid contains acetic acid. 20. The method according to any one of Embodiments 16 to 19, wherein the above acid is present in an amount of 0.01 to 20 volume equivalents based on compound B or a salt thereof. 21. The method according to any one of Embodiments 16 to 20, wherein the above acid is present in an amount of 0.1 to 10 volume equivalents based on compound B or a salt thereof. 22. The method according to any one of Embodiments 16 to 21, wherein the above acid is present in an amount of 0.5 to 3 volume equivalents based on compound B or a salt thereof. 23. The method according to Embodiment 22, wherein the above acid is present in an amount of 1 to 2.5 volume equivalents based on compound B or a salt thereof. 24. The method according to any one of Embodiments 1 to 23, wherein the mixing is carried out in the presence of up to 1.5 molar equivalents of water based on compound B or a salt thereof. 25. The method according to any one of Embodiments 1 to 24, wherein the mixing is carried out in the absence of water. 26. The method according to Embodiment 24, wherein water is present in an amount of 0.5 molar equivalents based on compound B or a salt thereof. 27. The method according to any one of Embodiments 1 to 26, wherein the mixing is carried out at a temperature of 20°C to 200°C. 28. The method according to Embodiment 27, wherein the mixing is carried out at 70°C to the reflux temperature of the solvent. 29. The method according to Embodiment 27, wherein the above mixing is carried out at a temperature of 50°C to 200°C. 30. The method according to Embodiment 29, wherein the above mixing is carried out at a temperature of 70°C to 190°C. 31. The method according to Embodiment 30, wherein the above mixing is carried out at a temperature of 130°C to 135°C. 32. The method according to any one of Embodiments 1 to 31, wherein the above mixing is carried out with a reaction time of 0.1 minutes to 48 hours. 33. The method according to any one of Embodiments 1 to 32, wherein the above mixing is carried out over a reaction period of 4 to 36 hours. 34. The method according to any one of Embodiments 1 to 33, wherein the above mixing is carried out over a reaction period of 8 to 24 hours. 35. The method according to any one of Embodiments 1 to 34, wherein the above mixing is carried out over a reaction time of 16 hours. 36. The method according to any one of Embodiments 1 to 31, wherein the above mixing is performed with a residence time of 0.1 to 120 minutes. 37. The method according to embodiment 36, wherein the above mixing is performed with a residence time of 1 to 60 minutes. 38. The method according to embodiment 37, wherein the above mixing is performed with a residence time of 10 to 40 minutes. 39. The method according to embodiment 38, wherein the above mixing is performed with a residence time of 15 to 30 minutes. 40. The method according to embodiment 39, wherein the above mixing is performed with a residence time of 25 to 30 minutes. 41. The method according to any one of embodiments 1 to 31 and 36 to 40, wherein the above mixing is carried out in a plug flow reactor. 42. The above isolation process, (a) A step of cooling the above reaction mixture to a temperature of 0°C to 50°C to form a cooling solution, (b) A step of adding water to the above cooling solution, (c) The method according to any one of Embodiments 1 to 41, comprising the step of (b) precipitation of the apremilast from the solution formed in step (b) to isolate the apremilast. 43. The method according to Embodiment 42, further comprising the step of filtering the precipitated apremilast of step (c). 44. The method of Embodiment 42, further comprising the step of adding crystalline apremilast to the cooling solution such that the precipitate of step (c) yields crystalline apremilast. 45. The method according to any one of Embodiments 1 to 41, wherein the isolation step includes continuous crystallization using a mixed suspension mixed product removal (MSMPR) crystallizer, parallel filtration, or a combination thereof. 46. A method for isolating apremilast from a reaction mixture containing crude apremilast and DMSO, (a) A step of cooling the above reaction mixture to a temperature of 0°C to 50°C to form a cooling solution, (b) A step of adding water to the above cooling solution, (c) A step of precipitating apremilast from the solution formed in step (b) to form precipitated apremilast, (d) A method comprising the step of isolating the precipitated apremilast. 47. The method according to Embodiment 46, wherein the isolation step described above is performed by filtration. 48. The method according to Embodiment 46 or 47, wherein step (b) further comprises adding crystalline apremilast to the cooling solution. 49. The method according to any one of embodiments 46 to 48, wherein the precipitated apremilast is crystalline. 50. A method for preparing apremilast, (a) A step of forming an apremilast in a reaction mixture by mixing (1) a first solution containing 3-acetamidophthalic anhydride (compound A) in a first solvent and (2) a second solution containing (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B) or a salt thereof in a second solvent, wherein the mixing is carried out in a continuous process apparatus. (b) A step of isolating the apremilast from the reaction mixture, wherein the isolation step is (i) A step of cooling the reaction mixture to a temperature of 0°C to 50°C, (ii) Adding water to the cooled reaction mixture, (iii) A step of precipitating apremilast from the mixture of step (ii), (iv) A method comprising the step of isolating the precipitated apremilast. 51. A method for preparing crystalline apremilast, (a) A step of forming an apremilast in a reaction mixture by mixing (1) a first solution containing 3-acetamidophthalic anhydride (compound A) in a first solvent and (2) a second solution containing (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B) or a salt thereof in a second solvent, wherein the mixing is carried out in a continuous process apparatus. (b) A method comprising the step of isolating crystalline apremilast from the reaction mixture by continuous crystallization and parallel filtration. 52. The method according to Embodiment 46, wherein the continuous crystallization described above includes the use of a mixed suspension mixed product removal (MSMPR) crystallizer.
[0050] Embodiments will be understood in more detail by referring to the following examples. These examples are intended to be illustrative of, but not limited to, the pharmaceutical compositions and dosage forms provided herein. [Examples]
[0051] The following embodiments illustrate the processes of the present disclosure, but should not be construed as limiting their scope in any way.
[0052] Example 1 This specification provides an example of a continuous reaction process for preparing apremilast and subsequently performing continuous crystallization of apremilast, as shown overall in Figure 1. 3-Acetamidophthalic anhydride (compound A, 1.059 kg, 0.99 equivalents) was dissolved in DMSO (14.23 L, 10 L / kg) in a first feed tank. (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B, 1.425 kg, 1.0 equivalent) was dissolved in DMSO (1.43 L, 1.0 L / kg) in a second feed tank, and acetic acid (3.56 L, 2.5 L / kg) was added to the solution in the second feed tank. The contents of the first and second feed tanks were pumped into a plug-flow reactor at rates of 9.96 mL / min and 4.0 mL / min, respectively. The reaction flow was mixed and heated at 130°C for an average residence time (τ) of 25 minutes to form crude apremilast. To isolate the apremilast, the reaction flow was sequentially passed through a series of three MSMPR vessels. In the first of the three MSMPR vessels, water and the reaction flow were simultaneously added to a seed bed containing DMSO, water, and crystalline apremilast species to obtain a mixture containing 30% water, while the temperature of the reaction flow was maintained at 25°C with stirring. Subsequently, the resulting slurry was pumped into the second MSMPR vessel, and water was added to obtain a mixture containing 40% water. The slurry was further transferred to the third MSMPR for further aging. The average residence time in each of the three MSMPRs was 60 minutes. The combined apremilast product was washed with water and ethanol and dried. In the continuous reaction process, the reactants were added simultaneously, and the product was discharged from the process system.
[0053] In the alternative process of Example 1, the continuous reaction process includes a number of discrete residence times during which the material properties of the system reach a steady state and are maintained constant over time, so that the process is uniform in terms of product output.
[0054] Example 2 In another example of a continuous reaction process for the preparation of apremilast and subsequent continuous crystallization of apremilast, compound A (222.9 g / 0.99 equivalents) was dissolved in DMSO (3.0 L, 10 L / kg compound B) in a first feed tank, compound B (300 g, 1.00 equivalent) was dissolved in DMSO (0.3 L, 1 L / kg) in a second feed tank, and acetic acid (0.75 L, 2.5 L / kg) and water (10.2 mL, 0.034 L / kg) were added to the second feed tank. The contents of the first and second feed tanks were pumped into a plug-flow reactor, the reaction flow was mixed axially, and heated at 130°C for an average residence time (τ) of 25 minutes to form crude apremilast. The crude reaction flow was collected and stored. Apremilast was then isolated from the stored reaction flow. The first volume of the stored reaction stream was crystallized using MSMPR as described above, and the second volume was crystallized by batch crystallization. Water (poor solvent) was then added directly to the stored reaction stream, followed by filtering, washing, and drying of the apremilast precipitate. Apremilast was produced in 98% yield.
[0055] Example 3 As outlined in Figure 2, apremilast with batch crystallization was prepared using a continuous reaction process and a batch crystallization process. Compound A (440 g, 0.99 equivalents) was dissolved in DMSO (6 L, 10 L / kg Compound B) in a first feed tank, and Compound B (594 g, 1 equivalent) was dissolved in DMSO (0.6 L, 1 L / kg) in a second feed tank, with acetic acid (1.5 L, 2.5 L / kg) and water (0.2 L, 0.034 L / kg) added to the second feed tank. The contents of the first and second feed tanks were pumped into a plug-flow reactor, the reaction flow was mixed axially, and the mixture was heated at 130°C for an average residence time (τ) of 20 minutes to form crude apremilast. The crude reaction stream was collected, and apremilast was then isolated from the reactant stream so that it was produced at a rate of 43 g / hour. The apremilast was crystallized by batch crystallization and added directly to the reaction stream with water (poor solvent) stored. Subsequently, the apremilast precipitate was filtered, washed, and dried.
[0056] Example 4 Further experiments on continuous process manufacturing were conducted at various temperatures, flow rates, volumes, and residence times. Solutions of compound A (0.99 equivalents, 0.35 mol / L) and compound B (1.0 equivalent, 0.88 mol / L) with flow rates of 1.57 mmol / min and 1.58 mmol / min, respectively, were reacted in a PFR with a volume of 125.61 mL and a residence time of 20 minutes. The reaction flow was then heated to a temperature of 130°C, producing apremilast at a daily processing rate of approximately 43.33 g / hour and approximately 1.04 kg / 24 hours.
[0057] Example 5 Solutions of compound A (0.99 equivalents, 0.35 mol / L) and compound B (1.0 equivalent, 0.88 mol / L), with flow rates of 1.31 mmol / min and 1.32 mmol / min respectively, were reacted in a PFR with a volume of 130.84 mL and a residence time of 25 minutes. The reaction flow was then heated to a temperature of 130°C to produce apremilast at a daily processing rate of approximately 36.11 g / hour and approximately 0.87 kg / 24 hours.
[0058] Example 6 Apremilast was produced using a batch method (a method in which all reactants are added before the start of processing and discharged at the end of processing), with DMF used as the polar aprotic solvent. Compound B (5.0 g, 1.0 equivalent) and water (0.17 mL, 0.034 mL / g) were added to a 100 mL EasyMax reactor, and DMF (30 mL, 6 mL / g) was added to the reactor to obtain a clear solution. The temperature was set to 20°C, and acetic acid (13 mL, 2.5 mL / g) was slowly added by syringe. Compound A (3.8 g, 0.99 equivalents) was then added to the reactor, and the reaction mixture was heated to 70°C. The reaction was monitored by UPLC and completed after 18 hours. Crude apremilast was produced in 75% yield.
[0059] Example 7 Apremilast was prepared by a batch process using DMSO as a polar aprotic solvent. A 100 mL EasyMax reactor was fitted with a temperature probe, reflux condenser, nitrogen inlet, and EasySampler probe, and compound B (6.02 g, 1 equivalent), anhydrous DMSO (36 mL, 6 mL / g), and water (0.20 mL, 0.034 mL / g) were added sequentially. Upon addition of DMSO (compound B was completely dissolved), a clear solution was obtained. The reaction mixture was cooled to 20°C, and then acetic acid (15 mL, 2.5 mL / g) was slowly added using a syringe. Solid compound A (4.48 g, 0.99 equivalents) was added, and the temperature was raised to 70°C over 1 hour, after which the reaction mixture was cooled to 35°C. The reaction was carried out until it was complete after 10 hours.
[0060] Example 8 Apremilast can be prepared by batch crystallization. To a reaction mixture containing crude apremilast (which may be the product of a batch or continuous manufacturing process), water (6.00 mL, 1.0 mL / g) was added dropwise using a syringe pump over 15 minutes at 35°C, and the mixture was stirred at 35°C for 20 minutes. 50 mg of apremilast seed (0.5 wt%) was added to the solution. The solution was immediately observed to become cloudy. The slurry was aged at 35°C for 1 hour, and then 3 volumes of water (18 mL, 3.0 mL / g) were added using a syringe pump over 1 hour. The cloudy solution was cooled to 15°C over 90 minutes, and then stirred overnight at 15°C. The slurry was filtered, washed with water (25 mL), and dried overnight under nitrogen sweep. Crystalline apremilast (9.47 g) was obtained (99.57% purity by qnmr, 99.86 LCAP purity), and this was... 11H NMR was performed (1H NMR (500 MHz, CD₃SOCD₃, 300 K) δ (ppm) = 9.69 (s, 1H), 8.46 (d, J=8.3 Hz, 1H), 8.02-7.97 (m, 2H), 7.77 (dd, J=7.4, 8.3 Hz, 1H), 7.68-7.63 (m, 1H), 7.58-7.50 (m, 2H), 7.50-7.44 (m, 2H), 7.43-7.32 (m, 3H), 7.09 (d, J=2.2 Hz, 1H), 7.00 (dd, J=2.0, 8.5 Hz, 1H), 6.94 (d, J=8.4 Hz, 1H), 5.80 (dd, J=4.3, 10.5 Hz, 1H), 5.36 (s, 2H), 4.37 (dd, J=10.6, 14.3 Hz, 1H), 4.16 (dd, J=4.3, 14.3 Hz, 1H), 4.02 (q, J=7.0 Hz, 1H), 3.74 (s, 1H), 3.32 (s, 1H), 3.03 (s, 1H), 2.19 (s, 1H), 1.32 (t, J=6.9 Hz, 1H)).
[0061] Example 9 Comparative Example (THF Batch Synthesis): A 100 mL EasyMax reactor was equipped with a temperature probe, reflux condenser, nitrogen inlet, and EasySampler probe. Compound B (6.00 g, 1.0 equivalent), THF (36 mL, 6.0 mL / g), and water (0.20 mL, 0.034 mL / g) were added sequentially. The reaction mixture was cooled to 15°C, and then acetic acid (15 mL, 2.5 mL / g) was slowly added over 2 minutes using a syringe while maintaining the internal reaction temperature below 25°C. The temperature was raised to 72°C, and compound A (4.6 g, 0.99 equivalents) was added as a solid. The reaction mixture was held at 72°C for 21 hours, then cooled to 30°C, and diluted with isopropyl acetate (51 mL, 8.5 mL / g). Next, 30 mL of 10% monobasic sodium phosphate solution (5.0 mL / g) was added using a syringe pump over 30 minutes, followed by stirring for another 30 minutes. The mixture was transferred to a separatory funnel, and the aqueous layer was removed. The organic layer was washed twice more with 30 mL of 10% monobasic sodium phosphate solution (5.0 mL / g), followed by washing with 30°C water (30 mL, 5.0 mL / g). Isopropyl acetate (48 mL, 8.0 mL / g) was added, and the solvent was removed by rotary evaporation. The residue was concentrated again from isopropyl acetate (48 mL, 8.0 mL / g), and the residue was dissolved in isopropyl acetate (39 mL, 6.5 mL / g) in a clean 100 mL EasyMax reactor. The solution was heated to 35°C, methyl t-butyl ether (MTBE) (9.0 mL, 1.5 mL / g) was added, and the mixture was stirred for 45 minutes until a turbid solution was obtained. MTBE (48 mL, 8.0 mL / g) was added over 2 hours using a syringe pump. After addition, the slurry was cooled to 15°C over 80 minutes and kept at 15°C overnight. The resulting slurry was filtered, washed with MTBE (18.0 mL, 3.0 mL / g), and dried to obtain crystalline apremilast (8.63 g, 97.2 wt% by qNMR, yield 84%).
[0062] While examples of specific embodiments are provided herein, it will be apparent to those skilled in the art that various changes and modifications can be made. Such changes are also intended to be included within the scope of the appended claims. Non-limitingly, the present invention includes the following embodiments. [Aspect 1] A method for preparing apremilast, (1) A first solution containing 3-acetamidophthalic anhydride (compound A) or a salt thereof in a first solvent, and (2) a second solution containing (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B) or a salt thereof in a second solvent, to form an apremilast in the reaction mixture, The steps include adding water to the reaction mixture to isolate the apremilast, Methods that include... [Aspect 2] The method according to Embodiment 1, wherein compound A or a salt thereof is present in an amount of 0.4 to 1.5 molar equivalents based on compound B or a salt thereof. [Aspect 3] The method according to embodiment 2, wherein compound A or a salt thereof is present in an amount of 0.8 to 1.2 molar equivalents based on compound B or a salt thereof. [Aspect 4] The method according to embodiment 3, wherein compound A or a salt thereof is present in an amount of 0.99 molar equivalents based on compound B or a salt thereof. [Aspect 5] The method according to any one of embodiments 1 to 4, wherein compound A is not in salt form. [Aspect 6] The method according to any one of embodiments 1 to 5, wherein the first solvent and the second solvent are the same solvent. [Aspect 7] The method according to any one of embodiments 1 to 6, wherein the first solvent and the second solvent are different solvents. [Aspect 8] The method according to any one of embodiments 1 to 7, wherein the first solvent is a polar aprotic solvent. [Aspect 9] The method according to any one of embodiments 1 to 8, wherein the second solvent is a polar aprotic solvent. [Aspect 10] The method according to embodiment 8 or 9, wherein the polar aprotic solvent has a boiling point of about 40°C to about 200°C at 1 atm. [Aspect 11] The method according to any one of embodiments 8 to 10, wherein the polar aprotic solvent has 0 to 10% by weight of water. [Aspect 12] The method according to any one of embodiments 8 to 10, wherein the polar aprotic solvent is anhydrous. [Aspect 13] The method according to any one of embodiments 8 to 12, wherein the polar aprotic solvent has a dielectric constant of 10 to 50 at room temperature and 1 atmosphere. [Aspect 14] The polar aprotic solvent is acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAC), N-methyl-2-pyrrolidone (NMP), hexamethylphosphoramide (HMPA), N,N'-dimethylpropylene urea (DMPU), sulfolane, dihydrolevoglucocenone, 1,3-dimethyl-2-imidazolidinone (DMI), or a combination thereof, as described in Embodiments 8-1. The method described in any one of item 3. [Aspect 15] The method according to any one of embodiments 8 to 14, wherein the polar aprotic solvent comprises dimethyl sulfoxide (DMSO). [Aspect 16] The method according to any one of embodiments 8 to 15, wherein the mixing is carried out in the presence of an acid. [Aspect 17] The method according to embodiment 16, wherein the acid is an alkyl sulfonic acid, an aryl sulfonic acid, an alkyl carboxylic acid, or an aryl carboxylic acid. [Aspect 18] The method according to embodiment 16 or 17, wherein the acid is selected from the group consisting of acetic acid, methylsulfonic acid, tolylsulfonic acid, trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, chloroacetic acid, benzenesulfonic acid, trifluic acid, ethylsulfonic acid, formic acid, propionic acid, benzoic acid, salicylic acid, and oxalic acid. [Aspect 19] The method according to any one of embodiments 16 to 18, wherein the acid comprises acetic acid. [Aspect 20] The method according to any one of embodiments 16 to 19, wherein the acid is present in an amount of 0.01 to 20 volume equivalents based on compound B or a salt thereof. [Aspect 21] The method according to any one of embodiments 16 to 20, wherein the acid is present in an amount of 0.1 to 10 volume equivalents based on compound B or a salt thereof. [Aspect 22] The method according to any one of embodiments 16 to 21, wherein the acid is present in an amount of 0.5 to 3 volume equivalents based on compound B or a salt thereof. [Aspect 23] The method according to embodiment 22, wherein the acid is present in an amount of 1 to 2.5 volume equivalents based on compound B or a salt thereof. [Aspect 24] The method according to any one of embodiments 1 to 23, wherein the mixing is carried out in the presence of up to 1.5 molar equivalents of water based on compound B or a salt thereof. [Aspect 25] The method according to any one of embodiments 1 to 24, wherein the mixing is carried out in the absence of water. [Aspect 26] The method according to embodiment 24, wherein the acid is present in an amount of 0.5 molar equivalents based on compound B or a salt thereof. [Aspect 27] The method according to any one of embodiments 1 to 26, wherein the mixing is carried out at a temperature of 20°C to 200°C. [Aspect 28] The method according to embodiment 27, wherein the mixing is carried out at 70°C to the reflux temperature of the solvent. [Aspect 29] The method according to embodiment 27, wherein the mixing is carried out at a temperature of 50°C to 200°C. [Aspect 30] The method according to embodiment 29, wherein the mixing is carried out at a temperature of 70°C to 190°C. [Aspect 31] The method according to embodiment 30, wherein the mixing is carried out at a temperature of 130°C to 135°C. [Aspect 32] The method according to any one of embodiments 1 to 31, wherein the mixing is carried out with a reaction time of 0.1 minutes to 48 hours. [Aspect 33] The method according to any one of embodiments 1 to 32, wherein the mixing is carried out during a reaction time of 4 to 36 hours. [Aspect 34] The method according to any one of embodiments 1 to 33, wherein the mixing is carried out over a reaction period of 8 to 24 hours. [Aspect 35] The method according to any one of embodiments 1 to 34, wherein the mixing is carried out over a reaction time of 16 hours. [Aspect 36] The method according to any one of embodiments 1 to 31, wherein the mixing is performed with a residence time of 0.1 to 120 minutes. [Aspect 37] The method according to embodiment 36, wherein the mixing is performed with a residence time of 1 to 60 minutes. [Aspect 38] The method according to embodiment 37, wherein the mixing is performed with a residence time of 10 to 40 minutes. [Aspect 39] The method according to embodiment 38, wherein the mixing is performed with a residence time of 15 to 30 minutes. [Aspect 40] The method according to embodiment 39, wherein the mixing is performed with a residence time of 25 to 30 minutes. [Aspect 41] The method according to any one of embodiments 1 to 31 and 36 to 40, wherein the mixing is carried out in a plug flow reactor. [Aspect 42] The isolation step described above is a. A step of cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooling solution, b. The step of adding water to the cooling solution, c. A step of precipitating the apremilast from the solution formed in step (b) and isolating the apremilast, The method according to any one of embodiments 1 to 41, including the method described in any one of embodiments 1 to 41. [Aspect 43] The method according to embodiment 42, further comprising the step of filtering the precipitated apremilast of step (c). [Aspect 44] The method according to embodiment 42, further comprising the step of adding crystalline apremilast to the cooling solution such that the precipitate of step (c) yields crystalline apremilast. [Aspect 45] The method according to any one of embodiments 1 to 41, wherein the isolation step includes continuous crystallization using a mixed suspension mixed product removal (MSMPR) crystallizer, parallel filtration, or a combination thereof. [Aspect 46] A method for isolating apremilast from a reaction mixture containing crude apremilast and DMSO, a. A step of cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooling solution, b. The step of adding water to the cooling solution, c. A step of precipitating apremilast from the solution formed in step (b) to form precipitated apremilast, d. A step of isolating the precipitated apremilast, Methods that include... [Aspect 47] The method according to embodiment 46, wherein the isolation step is performed by filtration. [Aspect 48] The method according to embodiment 46 or 47, wherein step (b) further comprises adding crystalline apremilast to the cooling solution. [Aspect 49] The method according to any one of embodiments 46 to 48, wherein the precipitated apremilast is crystalline. [Aspect 50] A method for preparing apremilast, a. A step of forming an apremilast in a reaction mixture by mixing (1) a first solution containing 3-acetamidophthalic anhydride (compound A) in a first solvent and (2) a second solution containing (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B) or a salt thereof in a second solvent, wherein the mixing is performed in a continuous process apparatus. b. A step of isolating the apremilast from the reaction mixture, wherein the isolation step is: i. A step of cooling the reaction mixture to a temperature of 0°C to 50°C, ii. A step of adding water to the cooled reaction mixture, iii. A step of precipitating apremilast from the mixture of step (ii), iv. A step of isolating the precipitated apremilast, Methods that include... [Aspect 51] A method for preparing crystalline apremilast, a. A step of forming an apremilast in a reaction mixture by mixing (1) a first solution containing 3-acetamidophthalic anhydride (compound A) in a first solvent and (2) a second solution containing (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B) or a salt thereof in a second solvent, wherein the mixing is performed in a continuous process apparatus. b. A step of isolating crystalline apremilast from the reaction mixture by continuous crystallization and parallel filtration, Methods that include... [Aspect 52] The method according to embodiment 51, wherein the continuous crystallization includes the use of a mixed suspension mixed product removal (MSMPR) crystallizer.
Claims
1. A method for preparing apremilast, (1) A first solution containing 3-acetamidophthalic anhydride (compound A) or a salt thereof in a first solvent, and (2) a second solution containing (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethane-1-amine (compound B) or a salt thereof in a second solvent, are mixed in a continuous reaction process to form an apremilast in the reaction mixture. The steps include adding water to the reaction mixture to isolate the apremilast, Includes, The mixing is performed with a residence time of 0.1 to 120 minutes. method.
2. The method according to claim 1, wherein compound A or a salt thereof is present in an amount of 0.4 to 1.5 molar equivalents based on compound B or a salt thereof.
3. The method according to claim 1, wherein compound A is not in salt form.
4. The method according to claim 1, wherein the first solvent and the second solvent are the same solvent.
5. The method according to claim 1, wherein the first solvent and the second solvent are different solvents.
6. The method according to claim 1, wherein the first solvent is a polar aprotic solvent; or the second solvent is a polar aprotic solvent.
7. The method according to claim 6, wherein the polar aprotic solvent is acetonitrile, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAC), N-methyl-2-pyrrolidone (NMP), hexamethylphosphoramide (HMPA), N,N'-dimethylpropylene urea (DMPU), sulfolane, dihydrolevoglucocenone, 1,3-dimethyl-2-imidazolidinone (DMI), or a combination thereof.
8. The method according to claim 6, wherein the mixing is carried out in the presence of an acid.
9. The method according to claim 8, wherein the acid is selected from the group consisting of acetic acid, methylsulfonic acid, tolylsulfonic acid, trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, chloroacetic acid, benzenesulfonic acid, trifluic acid, ethylsulfonic acid, formic acid, propionic acid, benzoic acid, salicylic acid, and oxalic acid.
10. The method according to claim 8, wherein the acid is present in an amount of 0.01 to 20 volume equivalents based on compound B or a salt thereof.
11. The method according to claim 1, wherein the mixing is carried out in the presence of up to 1.5 molar equivalents of water based on compound B or a salt thereof.
12. The method according to claim 1, wherein the mixing is carried out at a temperature between 70°C and the reflux temperature of the first solvent or the second solvent.
13. The method according to claim 1, wherein the mixing is carried out in a plug flow reactor.
14. The isolation step described above is a. A step of cooling the reaction mixture to a temperature of 0°C to 50°C to form a cooling solution, b. The step of adding water to the cooling solution, c. A step of precipitating the apremilast from the solution formed in step (b) and isolating the apremilast, The method according to claim 1, including the method described in claim 1.
15. The method according to claim 14, further comprising the step of filtering the precipitated apremilast of step (c).
16. The method according to claim 14, further comprising the step of adding crystalline apremilast to the cooling solution such that the precipitate of step (c) yields crystalline apremilast.
17. The method according to claim 1, wherein the isolation step includes continuous crystallization using a mixed suspension mixed product removal (MSMPR) crystallizer, parallel filtration, or a combination thereof.
Citation Information
Patent Citations
A method of chiral resolution of the key intermediate of the synthesis of apremilast and its use for the preparation of pure apremilast
WO2016161996A1
A process for preparing the key intermediate of apremilast, using enzymatic resolution of the racemic amines
WO2016192694A1
Process for preparation of apremilast
WO2017033116A1
Processes for the preparation of apremilast and intermediates thereof
WO2017059040A1
